Parameter | Low MPO [11.7–145) | High MPO (145.2–347] | P value |
---|---|---|---|
Demographic characteristics | N = 20 |  N = 20 | |
Age, y | 50.90 ± 12.60 | 43.60 ± 12.10 | 0.07 |
Men, no. (%) | 20 (100) | 20 (100) | – |
Framingham risk score | 4.03 (1.24–5.58) | 1.56 (0.25–7.76) | 0.26 |
Race | 15 (75) | 14 (70) | > 0.99 |
Current smoker, no. | 20 (100) | 19 (95) | – |
Hypertension, no. | 18 (90) | 17 (85) | 0.66 |
BMI | 25.55 (24.30–28.35) | 26.05 (24.25–30.30) | 0.55 |
Waist:hip ratio | 0.99 (0.93–1.02) | 0.96 (0.91–1.02) | – |
Statin treatment, n (%) | 0 (0) | 0 (0) | – |
PASI score | 6.85 (2.40–11.45) | 6.70 (5.05–14.05) | 0.22 |
hsCRP, mg/L | 1.80 ± 1.80 | 7.95 ± 11.70 | 0.08 |
GlycA, µmol/L | 384.80 ± 48.80 | 440.36 ± 94.52 | 0.07 |
Neutrophils, K/µL | 3.30 ± 1.16 | 4.28 ± 1.04 | 0.01 |
Monocytes, K/µL | 0.50 ± 0.13 | 0.51 ± 0.13 | 0.11 |
Lymphocytes, K/µL | 1.70 ± 0.55 | 1.73 ± 0.41 | 0.82 |
Neutrophil-lymphocyte ratio | 2.0 ± 0.90 | 2.60 ± 0.90 | 0.09 |
Total cholesterol, mg/dL | 187 ± 23.90 | 178.30 ± 39.50 | 0.41 |
LDL cholesterol, mg/dL | 116.70 ± 27.16 | 111.30 ± 38.48 | 0.61 |
LDL particle number | 1264.40 ± 299.54 | 1182.45 ± 416.35 | 0.48 |
LDL particle size | 21.01 ± 0.63 | 20.93 ± 0.58 | 0.68 |
HDL cholesterol, mg/dL | 52.6 ± 14.8 | 50.40 ± 10.80 | 0.60 |
HDL particle number | 33.67 ± 5.80 | 31.68 ± 5.29 | 0.27 |
HDL particle size | 9.02 ± 0.49 | 9.18 ± 0.49 | 0.25 |
HDL cholesterol efflux capacity | 1.02 ± 0.20 | 0.89 ± 0.23 | 0.05 |
MPO concentration, ng/mL | 58.80 (19.0–91.10) | 187.8 (156.80–253.70) | < 0.001 |